Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Peter Schwartz is a partner in our New York office and the chair of our finance practice. He represents lenders and borrowers in leveraged finance transactions, and also has extensive experience in private equity and M&A.

Mr. Schwartz regularly represents a number of institutional lenders, private equity firms and their portfolio companies, and public and private companies, in direct, club and syndicated financing transactions, many of which involve cross-border components. He represents clients in a wide range of financial products, including senior secured and unitranche loans, second lien financings, mezzanine debt, subordinated notes, preferred stock, warrants, and structured financings. He also represents clients in the monetization of pharmaceutical royalty streams (structured both as sales to investors and as financings).

  • Private investment funds focused on growth, acquisition and special situation financings for pharmaceutical, biotechnology, medical device and healthcare companies in numerous secured debt, royalty and equity financings, ranging in value from $20 million to $300 million.
  • Private equity funds in senior secured and mezzanine financings for a number of their acquisitions and portfolio companies, ranging in value from $25 million to $500 million.
  • A major multinational corporation, in its global debt financings, including first, second and third lien financings, secured and unsecured high yield bonds, and credit facilities in Europe, Asia and Latin America, ranging in value from $200 million to $3.3 billion.
  • Private equity funds in numerous leveraged buyouts of companies in industries including life sciences, education, food service, healthcare services, automotive, branded goods, telecom, and financial services, ranging in value from $40 million to $350 million.
  • A private investment fund in numerous investments in regional banks and bank holding companies, in recapitalization transactions ranging in value from $15 million to $300 million.
  • A major multinational corporation in a multi-billion dollar unsecured revolving credit facility.
  • A venture-backed corporation in a number of secured financings, ranging in value from $25 million to $75 million.
  • A hedge fund in a $200 million secured financing supporting the purchase, by a private investment firm, of a specialty pharmaceutical company.
  • A leading hedge fund in the acquisition of a mortgage origination and servicing business.
  • A major international consumer goods company in the sales of a number of non-core businesses.
  • A major international life sciences company in a number of public and private acquisitions.
  • BTI Client Service All-Star, Finance (2015)
  • Legal 500 US, M&A - National Firms - Large Deals (2009)
  • Legal 500 US, Private Equity Buyouts - Middle Market (2008)